Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Vasakova (Prague, Czech Republic). Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis?  Real- world results from the EMPIRE registry.. 4880

Member's Comments

No comment yet.

Related content which might interest you: Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias? Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020 Year: 2021 Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Does early diagnosis of idiopathic pulmonary fibrosis matter? Real- world´s data from the EMPIRE registry Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Real world idiopathic pulmonary fibrosis in the EMPIRE registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey Source: Eur Respir Rev 2014; 23:225-230 Year: 2014 Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort Source: International Congress 2016 – The best is yet to come in terms of lung function Year: 2016 Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Incidence and prevalence of IPF in an insurance claims database: Assessing accuracy using medical records Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg). Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Real life patient experience of pirfenidone in a regional interstitial lung disease clinic Source: International Congress 2015 – IPF: from bench to bedside Year: 2015